Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus

2015162 citationsJournal Articlehybrid Open Access

Authors

Ian J. Neeland · The University of Texas Southwestern Medical Center

Darren K. McGuire · The University of Texas Southwestern Medical Center

Robert Ćhilton · The University of Texas Health Science Center at San Antonio

Susanne Crowe · Boehringer Ingelheim (Germany)

Søren S. Lund · Boehringer Ingelheim (Germany)

Hans J. Woerle · Boehringer Ingelheim (Germany)

Uli C. Broedl

Abstract

Empagliflozin significantly reduced weight and adiposity indices with the potential to improve cardiometabolic risk among patients with type 2 diabetes mellitus.

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Pancreatic function and diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes and Vascular Disease Research

Volume 13, Issue 2, pp. 119-126

DOI: 10.1177/1479164115616901

Field-Weighted Citation Impact: 8.88